Epidemiology of metastatic lung cancer in France between 2013 and 2021: Observational study using the French claims database
This study provides unpublished epidemiological data on metastatic lung cancer in France and confirms sex-differentiated trends in the rate of newly-diagnosed metastatic patients, already observed for all stages combined. A statistically significant decrease in the proportion of deaths among metastatic lung cancer patients is observed in both genders. These results underline the importance of ongoing investments in prevention and screening initiatives to reverse the incidence trends observed in women. Moreover, it highlights the criticality of therapeutic innovation in sustaining the increase in survival.
Authors
- C. Chouaïd (ORCID: https://orcid.org/0000-0002-4290-5524)
- Lionel Bensimon
- Manon Belhassen (ORCID: https://orcid.org/0000-0002-9478-5464)
- Jean‐Yves Blay (ORCID: https://orcid.org/0000-0001-7190-120X)
- Marion Apert
- Mélanie Nee (ORCID: https://orcid.org/0000-0001-7016-501X)
- Gérard de Pouvourville (ORCID: https://orcid.org/0000-0002-5941-6823)
- Valérie Guimard
- Clarisse Marchal
Institutions
- École Supérieure des Sciences Économiques et Commerciales (FR)
- Centre Léon Bérard (FR)
- CY Cergy Paris Université (FR)
- Hôpital Intercommunal de Créteil (FR)
Publication Details
- Journal
- Bulletin du Cancer
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1016/j.bulcan.2024.12.007
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Roche
- MSD France